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The molecular mechanism formation of secondary epiretinal membranes (ERMs) after proliferative diabetic retinopathy (PDR) or
primary idiopathic ERMs is still poorly understood. Therefore, the present study focused on the assessment of IGF1, IGF1R, and
IGFBP3 mRNA levels in ERMs and PBMCs from patients with PDR. The examined group comprised 6 patients with secondary
ERMs after PDR and the control group consisted of 11 patients with idiopathic ERMs. Quantification of IGF1, IGF1R, and IGFBP3
mRNAs was performed by real-time QRT-PCR technique. In ERMs, IGF1 and IGF1R mRNA levels were significantly higher in
patients with diabetes compared to control subjects. In PBMCs, there were no statistically significant differences of IGF1, IGF1R,
and IGFBP3 expression between diabetic and nondiabetic patients. In conclusion, our study indicated IGF1 and IGF1R differential
expression in ERMs, but not in PBMCs, of diabetic and nondiabetic patients, suggesting that these factors can be involved in the
pathogenesis or progression of proliferative vitreoretinal disorders. This trial is registered with NCT00841334.
1. Introduction
Proliferative diabetic retinopathy (PDR) is a common and
specific microvascular complication of diabetes mellitus.
Inflammation, angiogenesis, and fibrosis are primary pro-
cesses involved in the pathogenesis of PDR [1]. Moreover,
Snead et al. [2] suggested that hypoxia and neovascular
cytokine production may play an important role in epiretinal
membrane (ERM) formation of PDR patients.
Epiretinal membrane is a layer of pathologic tissue which
grows on the internal surface of the retina [3, 4]. ERMs
can be idiopathic (iERM) or secondary to some patho-
logic conditions, including proliferative diabetic retinopathy,
proliferative vitreoretinopathy (PVR), macular pucker, high
myopia, uveitis, and other retinal degenerative diseases [5].
Depending on duration and severity of ERMs, the symptoms
felt by patient can differ frommild to severemetamorphopsia,
decrease in visual acuity caused by retinal distortion and
problems such as vitreoretinal tractions or even tractional
retinal detachment [6]. It is known that ERMs in PDR
are mainly composed of new pathological vessels. On the
contrary, the idiopathic ERMs consist of a nonangiogenic
fibroglial tissue [7]. However, the molecular mechanism
formation of both the primary and secondary ERMs in
diabetic and nondiabetic patients is still poorly understood.
Several cytokines, including insulin-like growth factor
(IGF), are involved in the progression of ERMs [8–10]. The
IGF family is comprised of ligands: IGF1, IGF2, insulin;
six binding proteins (IGFBP1 through -6); and cell surface
receptors, including IGF1R, IGF2R, and insulin receptors [11].
Many recent studies suggested that IGF1 and IGF2 may be
involved in the pathogenesis of PDR; however, the exact role
has not been well understood yet [12, 13]. Recent reports
suggest that increases in IGF1 activity may contribute to
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retinal neovascularization characteristic for PDR [14, 15].
IGFs are also involved in stimulation of epiretinal membrane
contraction [9]. Additionally, IGF system is known to be
associated with inflammation process [16, 17].
Numerous attempts have been made to identify various
proteins in serum or mRNA in peripheral blood mononu-
clear cells (PBMCs), which could be easily accessed and act
as markers of intratissue processes in various diseases [13, 18].
However, local concentrations of different growth factors
in the retina may be more important than systemic levels
in the pathogenesis of diabetic retinopathy. There are only
few published data regarding differences between mRNA
levels of IGF in the eye tissues of diabetic and nondiabetic
patients [19–22]. Therefore, the present study focused on the
assessment of mRNA levels of IGF1, IGF1R, and IGFBP3 both
in ERMs and PBMCs frompatients with proliferative diabetic
retinopathy.
2. Materials and Methods
2.1. Subjects. The blood samples from 17 patients and sur-
gically removed ERMs from 17 eyes of these patients were
obtained and categorized into diabetic and nondiabetic ones.
The examined group comprised 6 patients (3 females and
3 males, mean age 72.9 years; range 66–80 years) with
secondary ERMs after PDR and the control group consisted
of 11 patients (8 females and 3males, mean age 69.7; range 61–
79 years)with iERMs (Table 1). All the patientswere treated in
the Department of Ophthalmology, University Hospital No.
5, Medical University of Silesia, Katowice, Poland.
The period between the diagnosis of the condition and
the actual surgery for the condition was between 2 and 16
months. Some patients presented and had surgery within
two month. When patients were asymptomatic or had good
visual acuity ERMs were diagnosed clinically that did not
require immediate surgery. The average duration in which
the membranes were present in the eye before removal was
6.4 months (range 3–10 months) for PDR and 8.6 months
(range 2–16 months) for iERM. All subjects underwent
a complete ophthalmic examination: best corrected visual
acuity (BCVA), tonometry, slit lamp examination of anterior
and posterior segment, ultrasonography of the eye, and
optical coherence tomography (OCT) of the central retina.
The criteria for inclusion into the molecular analysis were as
follows: patients of Caucasian race, both males and females,
aged ≥55 years, suffering from idiopathic ERMs or secondary
ERMs in PDR. Presence of ERM was proven in OCT
examination. All patients were qualified to surgical treatment
of ERM—unilateral pars plana vitrectomy (PPV).
The study was approved by the Bioethics Committee of
the Medical University in Katowice (KNW/0022/KB1/82/12)
in accordance with the Declaration of Helsinki regarding
medical research involving human subjects. All patients were
informed about the research and signed an informed consent
form.
2.2. Tissues. Samples of all ERMs were collected during
pars plana vitrectomy, using intraocular microforceps, and
Table 1: Selected clinical features of patients with secondary ERMs
after proliferative diabetic retinopathy and the control group with
idiopathic ERMs.
Characteristic Secondary ERMsgroup (𝑛 = 6)
Idiopathic ERMs











6.4 (3–10) 8.6 (2–16)
Visual acuity† 0.3 (0.01–0.5) 0.2 (0.02–0.4)
∗Values of clinical parameters are expressed as means (minimum–
maximum).
†Snellen chart.
were stored for 48 h at −70∘C until RNA extraction. Venous
blood samples were collected into EDTA-containing tubes
and peripheral mononuclear cells were isolated from 5mL
specimens derived from each patients by using Ficoll-Conray
density gradient centrifugation for 30min at 1500 rpm at
room temperature immediately after blood collection (spe-
cific gravity 1.077; Immunobiological Co., Gunma, Japan).
2.3. Ribonucleic Acid Extraction from Tissue Specimens. Total
RNA was extracted from ERMs and PBMCs using a TRIzol
reagent (Invitrogen, Carlsbad, CA, USA). RNA extracts were
treated with DNase I (MBI Fermentas, Vilnius, Lithuania)
according to the manufacturer’s instructions. The quality of
extracts was checked electrophoretically using 0.8% agarose
gel stained with ethidium bromide.The results were analyzed
and recorded using the 1D Bas-Sys gel documentation system
(Biotech-Fisher, Perth, Australia). Total RNA concentration
was determined by spectrophotometric measurement in 5𝜇L
capillary tubes using the Gene Quant II RNA/DNA Calcula-
tor (Pharmacia Biotech, Cambridge, UK).
2.4. Quantitative Real-Time Polymerase Chain Reaction Assay.
Detection of the expression of IGF1, IGF1R, IGFBP3, and
glyceraldehyde-3-phosphate (GAPDH) mRNAs was carried
out using a QRT-PCR technique with SYBR Green chem-
istry (SYBR Green Quantitect RT-PCR Kit, Qiagen) and
an Opticon DNA Engine Continuous Fluorescence detector
(MJ Research) as described previously [23]. All samples
were tested in triplicate. GAPDH for each sample was mea-
sured to exclude possible RT-PCR inhibitors.Oligonucleotide
primers, specific for IGF1, IGF1R, and IGFBP3, were designed
on the basis of reference sequences (GenBank accession no.
NM 000618.3, NM 000875.3, andNM 000598.4, resp.) using
Primer ExpressTM Version 2.0 software (PE Applied Biosys-
tems, Foster City, CA, USA). Detection of GAPDH mRNAs
was performed as described previously [23] (Table 2).
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Table 2: Characteristics of primers used for real-time QRT-PCR.















The thermal profile for one-step RT-PCR was as follows:
reverse transcription at 50∘C for 30min, denaturation at
95∘C for 15min, and 40 cycles consisting of the following
temperatures and time intervals: 94∘C for 15 s, 60∘C for
GAPDH, 61.1∘C for IGF1, 56.4∘C for IGF1R and 54.2∘C for
IGFBP3 for 30 s, and 72∘C for 30 s. Each run was completed
using melting curve analysis to confirm the specificity of
amplification and the absence of primer dimers. RT-PCR
products were separated on 6% polyacrylamide gels and
visualized with silver salts.
2.5. Quantification of Expression of Target Genes. To quantify
the results obtained with RT-PCR for IGF1, IGF1R, IGFBP3,
and GAPDH, a standard curve method was used [23, 24].
Commercially available standards of 𝛽-actin cDNA (TaqMan
DNA Template Reagent Kit, PE Applied Biosystems, Foster,
CA) were used at five different concentrations (0.6, 1.2, 3.0,
6.0, and 12.0 ng/𝜇L), to simultaneously detect the expression
profile of each investigated gene. For standards, the calcu-
lation of copy number values was based on the following
relationship: 1 ng of DNA = 333 genome equivalents (PE
Applied Biosystems). Amplification plots for each dilution
of a commercially available standard template were used to
determine the Ct values. A standard curve was generated by
plotting the Ct values against the log of the known amount
of 𝛽-actin cDNA copy numbers. Correlation coefficients for
standard curves ranged from 0.988 to 0.995 indicating a high
degree of confidence for measurement of the copy number of
molecules in each sample.
2.6. Statistical Analyses. Statistical analyses were performed
using Statistica 9.0 software (StatSoft, Tulsa, OK, USA), and
the level of significance was set at 𝑃 < 0.05. Values were
expressed as median with the 25th and 75th quartiles, and
minimum and maximum. The Mann-Whitney 𝑈-test was
applied to assess differences in the expression level of IGF1,
IGF1R, and IGFBP3. Correlations were evaluated using the
Spearman rank correlation test.
3. Results
3.1. Specificity of the Real-Time Reverse Transcription Poly-
merase Chain Reaction Assay. RT-PCR specificity for the
target genes was confirmed experimentally on the basis of
amplimers melting temperatures. For each RT-PCR product,
a single peak at expected temperatures was observed: IGF1,
77.6∘C; IGF1R, 77.4∘C; IGFBP3, 82.4∘C, and GAPDH, 80.0∘C
(data not shown). Gel electrophoresis also revealed the
presence of a single product of predicted length (data not
shown).
3.2. Differences in IGF1, IGF1R, and IGFBP3 Expression Level
between Diabetic and Nondiabetic Patients. IGF1 and IGF1R
mRNAs were detected in all tested ERMs and PBMCs
obtained from the control and study groups. However,
IGFBP3 was only detected in PBMCs of all patients. In the
ERMs, themRNA level of IGF1was significantly higher in the
patientswith diabetes (median= 271mRNAcopies/𝜇g of total
RNA) compared to the control iERMs of nondiabetic group
(median = 85mRNA copies/𝜇g of total RNA). In the case
of IGF1R, the expression was significantly greater in ERMs
after PDR (median = 1341mRNA copies/𝜇g of total RNA)
compared to the idiopathic ERMs (median = 938 mRNA
copies/𝜇g of total RNA) (𝑃 = 0.0224, Mann-Whitney 𝑈-test)
(Figure 1).
In PBMCs, there were no significantly different expres-
sions of IGF1, IGF1R, and IGFBP3 between diabetic
(median = 163mRNA copies/𝜇g of total RNA; 298mRNA
copies/𝜇g of total RNA; 1211mRNA copies/𝜇g of total
RNA, resp.) and nondiabetic patients (median = 144mRNA
copies/𝜇g of total RNA; 308mRNA copies/𝜇g of total RNA;
1209mRNA copies/𝜇g of total RNA, resp.) (IGF1 𝑃 = 0.6353,
IGF1R 𝑃 = 0.7250, IGFBP3 𝑃 = 0.9599, Mann-Whitney
𝑈-test) (Figure 2).
3.3. Correlations between IGF1, IGF1R, and IGFBP3Expression
Level and Time Interval between Diagnosis and Surgery.
There was no correlation between the time interval between
diagnosis of the condition and the actual surgery and the
expression of IGF1, IGF1R, and IGFBP3 both in the ERMs
and PBMCs of the diabetic samples. Corresponding to the
results obtained for diabetic patients, in iERMs and PBMCs
from the nondiabetic patients, no correlations between the
expression of IGF1, IGF1R, and IGFBP3 genes and time
interval between diagnosis of the condition and the actual
surgery were detected (Table 3).
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Table 3: The correlations between relative expression of IGF1, IGF1R, and IGFBP3 and time interval between diagnosis and surgery in the
ERMs and PBMCs of diabetic and nondiabetic patients.
Diabetic patients
ERMs IGF1 IGF1R PBMCs IGF1 IGF1R IGFBP3
Time interval between
diagnosis and surgery 𝑟 = 0.316 𝑟 = −0.316
Time interval between
diagnosis and surgery 𝑟 = 0.462 𝑟 = 0.103 𝑟 = −0.462
Nondiabetic patients
iERMs IGF1 IGF1R PBMCs IGF1 IGF1R IGFBP3
Time interval between
diagnosis and surgery 𝑟 = 0.065 𝑟 = 0.497
Time interval between
diagnosis and surgery 𝑟 = 0.153 𝑟 = 0.470 𝑟 = −0.442
































Figure 1: The mRNA levels of IGF1 and IGF1R in epiretinal
membranes of patients with proliferative diabetic retinopathy (PDR)
and in the control subjects with idiopathic ERMs (iERM). (Box and
whisker plots present medians ± quartiles and extreme values of
copy numbers per 1 𝜇g of total RNA, statistical significance: ∗𝑃 <
0.05, Mann-Whitney 𝑈-test).
4. Discussion
IGF1/IGF1R/IGFBPs complex can participate in the phys-
iological and pathological events that occur in the retina.
Previous research has revealed IGF1, IGF1R, and IGFBPs
expression in microvascular endothelial cells, pericytes and
retinal epithelial cells (RPE) in vitro [25–27]. Therefore,
it is suggested that these growth factors can also cause
progression of ERMs, especially during proliferative diabetic
retinopathy [11]. On the other hand, the level of IGFs in the
eye tissues may result, in part, from damage to the blood-
retinal barrier. Furthermore, the association between level
of IGFs in serum/PBMCs and the development of PDR is
still not fully explained [12]. Therefore, determination of


































Figure 2: The mRNA levels of IGF1, IGF1R, and IGFBP3 in periph-
eral blood mononuclear cells of patients with proliferative diabetic
retinopathy (PDR) and in the control subjects with idiopathic ERMs
(iERM). (Box and whisker plots present medians ± quartiles and
extreme values of copy numbers per 1𝜇g of total RNA, statistical
significance: ∗𝑃 < 0.05, Mann-Whitney 𝑈-test).
PBMCs in diabetic compared to nondiabetic patients using
real-time QRT-PCR seems to be important. In the present
study, IGF1, IGF1R, and IGFBP3 mRNA levels were detected
in PBMC samples, but in ERMs only IGF1 and IGF1RmRNAs
were determined. It can be explained that IGFBP3 did not
cause proliferation of retinal cells [28]. Moreover, Spoerri
et al. [29] showed that exogenous administration of IGFBP3
can induce growth inhibition and apoptosis of retinal cells.
On the other hand, it was reported that IGFBP3 is neu-
roprotective, antiapoptotic, anti-inflammatory after retinal
injury [30, 31] and may prevent the progression of PDR [32].
Previous research showed that also IGFs are not involved in
proliferation of these cells but in stimulation of epiretinal
membrane contraction [9]. In contrast, Spraul et al. [12] and
Takagi et al. [25] indicate that IGF1 and IGF2 can influence
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RPE cell migration and proliferation. In turn, Ruberte et al.
[33] determined that neovascularization was consistent with
increased vascular endothelial growth factor level induced by
IGF1 in retinal cells.
Statistically significant higher mRNA levels of IGF1 and
IGF1R in the ERMs of patients with PDR compared to the
control subjects with iERMs in our results confirmed that
the IGFs may play a key role in development or progression
of PDR. Similar results were demonstrated by other authors
who found significantly higher protein level of IGF1 in PDR
than in control patient but in human vitreous samples [34–
36], whereas Gerhardinger et al. [37] reported a lower mRNA
levels of IGF1 in diabetic retinas obtained postmortem from
humandonors and they did not observe a changed expression
of IGF1R.
Interestingly, our results for the quantitative analysis of
IGF1, IGF1R, and IGFBP3 in PBMCs revealed no statistically
significant differences of all three genes between diabetic and
nondiabetic patients which might suggest that the processes
occurring in the eye tissues are not affected by systemic
expression levels of these cytokines during diabetes. Corre-
sponding to our results, Payne et al. [13] and Spranger et al.
[36] found that diabetic subjects had similar IGF1 level com-
pared to nondiabetic subjects but in serum samples. Similarly,
other authors showed no correlation between serum IGF1
levels and the development or progression of PDR [13, 38].On
the other hand, several studies contradict these findings; for
example, Dills et al. [39] andMerimee et al. [40] have revealed
higher serum IGF1 levels in diabetic patients. Moreover,
Chen et al. [14] suggested that serum IGF1 level may be a
contributing factor in diabetic retinopathy. However, these
differences may be a result of the assay method used to
measure IGF1 levels. Additionally, transport mechanisms for
IGFs and IGFBPs between the blood and the eye are not very
well known and may depend on the blood-retinal barrier
whose disruption is an important event in pathogenesis
of diabetic retinopathy and other ocular disorders [12].
Haurigot’s studies demonstrated that intraocular IGF1, but
not systemic IGF1, is sufficient to trigger blood-retinal barrier
breakdown [15]. It may suggest that treatment strategies
should be designed to counteract local than systemic IGF1
effects [15]. In contrast, Spranger et al. [36] indicated that
breakdown of the blood-retinal barrier and serum levels of
IGF mainly determined intravitreal IGF levels rather than
local production. The disruption of the blood-retinal barrier
can cause also the infiltration of immunologically competent
cells into PDR membranes; therefore, the inflammatory
reactions may play a role in the development of the epiretinal
membrane in PDR [41]. It is also known that IGF1 has
anti-inflammatory effects and it can be negatively correlated
with inflammatory markers [16]. No correlation between the
vitreous and serum levels of various growth factors in patients
with PDR and nonproliferative diabetic retinopathy was also
observed [42–44]. The lack of correlations between serum
and intraocular tissue levels can suggest that serum/PBMC
levels of various growth factors may not be a useful predictor
of the diabetic retinopathy severity [42, 43]. Moreover, our
research did not show any correlation between IGF1, IGF1R,
and IGFBP3 mRNA levels and the time interval between
diagnosis of the condition and the surgery.
In conclusion, our study indicated IGF1 and IGF1R dif-
ferential expression in ERMs, but not in PBMCs, of diabetic
and nondiabetic patients, suggesting that these factors can be
involved in the pathogenesis or progression of proliferative
vitreoretinal disorders. Unfortunately,major limitation of our
study is a relatively small number of samples. However, analy-
sis of ocular samples is often difficult because of the technical
obstacles associated with extracting sufficient quantities of
the samples. Therefore, there is a need to study a larger
population and carry out further analysis, for example, on
protein levels, in order to clarify the contribution of these
intravitreal growth factors in the development of diabetic and
nondiabetic ERMs. Moreover, this will help to identify better
treatment strategies for proliferative diabetic retinopathy.
Conflict of Interests
The authors declare that there is no conflict of interests.
References
[1] A. M. Abu El-Asrar, M. Imtiaz Nawaz, D. Kangave, M. M. Sid-
diquei, and K. Geboes, “Osteopontin and other regulators of
angiogenesis and fibrogenesis in the vitreous from patients with
proliferative vitreoretinal disorders,” Mediators of Inflamma-
tion, vol. 2012, Article ID 493043, 8 pages, 2012.
[2] D. R. J. Snead, S. James, and M. P. Snead, “Pathological changes
in the vitreoretinal junction 1: epiretinal membrane formation,”
Eye, vol. 22, no. 10, pp. 1310–1317, 2008.
[3] W. E. Smiddy, A. M. Maguire, W. R. Green et al., “Idiopathic
epiretinal membranes: ultrastructural characteristics and clini-
copathologic correlation. 1989,”Retina, vol. 25, no. 5, pp. 811–821,
2005.
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